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Saccharomyces cerevisiae is a well known yeast used safely from ancient times in many 
biotechnological applications. Nowadays, there is an increasing interest in using yeast as probiotic. 
Dimethyl nitrosamine (DMN) has been used to induce liver fibrosis in rats. Yeast has been used side by 
side with the DMN to evaluate the role of its use as a probiotic in the protection against liver fibrosis. 
Six groups of rats have been used to represent negative and positive controls and other four groups 
which have been treated by DMN for two weeks and killed after 35 or 60 days. Two of the DMN 
treatment groups have been fed by yeast from the first 35 to 60 days, respectively. The results show 
that yeast has no side effect on each of glutamate-oxaloacetate-transaminase (GOT), glutamate-
pyruvate-transaminase (GPT) and alkaline phosphatase (ALP) enzyme activities. DMN showed a 
significant effect on those enzymes. Feeding with yeast for 35 days showed a minor improvement, 
while feeding them for 60 days showed a significant improvement. Moreover, the expressions of 
interleukin 1-alpha (IL-1ɑ) and interleukin-7 receptor (IL-7r) have been evaluated using reverse 
transcription polymerase chain reaction (RT-PCR). The study includes also the analysis of liver 
histopathology. This study shows the importance of using yeasts as probiotics in the protection 
against liver injury.  
 





The term "probiotic" means "for life". It generally refers to 
concentrated supplements of beneficial bacteria similar to 
those that occur naturally in the intestinal tract. Most 
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digestive process and the highly acidic conditions in the 
stomach (Heilpern and Szilagyi, 2008; Heimbach, 2008; 
Macfarlane and Cummings, 1999a, b; Marchand and 
Vandenplas, 2000). Yeast are used in many industrial, 
medicinal and pharmaceutical applications (Kumura et 
al., 2004; Brophy et al., 2008; Buts, 2005; Cohen, 2007; 
Gerasimidis et al., 2008; Huebner et al., 2008; Rosen et 
al., 2007). In recent years, showing an increasing interest 
in using yeast as probiotic has been observed (Beverage, 
2006; van der Aa Kule et al., 2005; Sullivan and Nord, 
2003). Saccharomyces cerevisiae var boulordii has been 
used widely for treating a range of diarrheal disorders 
(van der Aa Kule et al., 2005; Czervoka and Rampal, 
2002).  Many other yeasts species have been described 





Yarrowia lipolytica, Idastrandia orientalis, Pichia farinose 
and Pichia anomala (Beverages, 2006). Different kinds of 
probiotic have been examined as a potential source for 
cancer treatment (Chen et al., 2009). In this study, we 
investigated the role of S. cerevisiae in rats liver 
protection against fibrosis during the treatment with 
dimethyl nitrosamine (DMN) as a mutagen. 
 
 
MATERIALS AND METHODS 
 
Preparation of Saccharomyces cerevisiae 
 
S. cerevisiae strain bought from local market as dry granules has 
been used in this study. It was prepared as a semi wet paste. The 
strain was subjected to activation before its use by mixing it with 5 
ml of 2% glucose for each 25 g under aseptic conditions, and left at 
37°C till suitable dryness which enabled better mixing with the 






Adult male Wistar albino rats, ageing approximately three months 
and ranging in weight from 150 ± 10 g, were obtained from the 
Animal Care Center, College of Pharmacy, King Saud University, 
Riyadh, Saudi Arabia. The animals were housed in metabolic cages 
under controlled environmental conditions (25°C and a 12 h 
light/dark cycle). Animals had free access to pulverized standard rat 
pellet food and tap water. The protocol of this study has been 
followed by the instruction of the Research Ethics Committee of 





Chemicals used in this research include: glutamate-oxaloacetate-
transaminase (GOT), glutamate-pyruvate-transaminase (GPT) and 
alkaline phosphatase (ALP) purchased from USA-Randox 
Laboratories
®
; DMN purchased from Sigma Chemical
®
, St. Louis, 
MO, USA; TRIzol reagent purchased from Invitrogen
®
 (Grand 
Island, NY); High-Capacity cDNA reverse transcription kits and 
SYBR Green PCR Master Mix purchased from Applied Biosystems
®
 
(Foster City, CA, USA) and primers purchased from MSAM 
International Est
®





Six groups of rats have been investigated and represented: group 
1, 10 rats as negative control (without any treatment only food for 
60 days); group 2, 10 rats fed as the above group but yeast was 
added as a positive control; group 3, 10 rats injected 
intraperitoneally (IP) with DMN for two weeks during the feeding 
with food containing yeast for 35 days; group 4, 10 rats injected IP 
with DMN for two weeks during the feeding period, with food 
containing yeast for 60 days; group 5, 10 rats injected IP with DMN 
for two weeks during the feeding period, with food only for 35 days 
and group 6, 10 rats injected IP with DMN for two weeks during the 
feeding period, with food only for 60 days. The amount of DMN was 
100 M (1 g/kg). The rats were left after last feeding overnight 
without feeding and were weighed before sacrifice. At the end of 
the treatment protocol, rats were been subjected to complete 
anesthesia using diethyl ether. Blood sample from each rat was 
collected. The abdominal cavities were immediately opened and the   




liver was excised, weighed, and then washed with cold 0.1 M 
phosphate buffer, pH 7.4.  
 
 
Biochemical analysis (GOT, GPT and ALP) 
 
The blood sample were collected from each rat in sterilize 
eppendorf tube as above, stored in room temperature (20°C) for 2 
min, then centrifuge at 2000 rpm. GOT, GPT and ALP activities 
were determined spectrophotometrically with the aid of USA-
Randox
®
 kit. The increase in the absorbance against time was 
measured at different time interval and the best slope was 
determined for each sample. The activity from each slope was 
determined against standard curve for each of GOT, GPT and ALP. 
 
 
RNA extraction and cDNA synthesis  
 
Total RNA from the liver tissue homogenate was isolated using 
TRIzol reagent (Invitrogen
®
). The isolation method was performed 
according to the manufacturer's instructions and quantified by 
measuring the absorbance at 260 nm; the RNA quality was 
determined by measuring the 260/280 ratio. The cDNA synthesis 
was performed using the high-capacity cDNA reverse transcription 
kit (Applied Biosystems
®
) according to the manufacturer's 
instructions. Briefly, 1.5 g of total RNA from each sample was 
added to a mixture of 2.0 l of 10× reverse transcriptase buffer, 0.8 
l of 25× dNTP mix (l00 mM), 2.0 l of l0× reverse transcriptase 
random primers, 1.0 l of MultiScribe reverse transcriptase, and 3.2 
l of nuclease-free water. The final reaction mixture was kept at 
25°C for 10 min, heated to 37°C for 120 min, heated for 85°C for 5 
s, and finally cooled to 4°C.  
 
 
Quantification of mRNA expression by reverse transcription 
polymerase chain reaction (RT-PCR)  
 
Quantitative analysis of mRNA expression of target genes was 
performed by RT-PCR through subjecting the resulting cDNA from 
the above preparation to PCR amplification using 96-well optical 
reaction plates in the ABI Prism 7500 System (Applied 
Biosystems
®
). The 25 l reaction mixture contained 0.1 l of 10 M 
forward primer and 0.1 l of 10 M reverse primer (40 M final 
concentration of each primer), 12.5 l of SYBR Green Universal 
Mastermix, 11.05 l of nuclease-free water, and 1.25 l of cDNA 
sample. The primers used in the current study were chosen from 
previously published studies as listed in Table 1. Assay controls 
were incorporated onto the same plate, namely, no-template 
controls to test for the contamination of any assay reagents. The 
real-time PCR data was analyzed using the relative gene 
expression (that is, ∆∆CT) method, as described in Applied 
Biosystems
®
 User Bulletin no. 2. Briefly, the data were presented as 
the fold change in gene expression normalized to the endogenous 





At the end of treatment, both control and experimental rats were 
euthanized using diethyl ether. The livers were collected from all 
the groups, fixed in 10% formalin in saline, dehydrated in ascending 
grades of ethyl alcohol, cleared in xylol and mounted in molten 
paraplast at 58 to 62°C. Thin sions (4 to 5 mm) were cut using 
microtome, and stained with hematoxylin and eosin, and then 
examined using a light microscope. Histological changes in the liver 
were scored for identification of organ architecture and presence of 
edema, inflammatory cell infiltrate, hemorrhage and ulceration. The  




Table 1. Forward and reverse primers used in this study. 
 
Gene Forward primer Reverse primer References 
IL-1ɑ GGAGGCCATAGCCCATGATTTAG TATTCTGGAAGCTGTGTAGGTGCTG Xia et al. (2010) 
IL-7r SCAGAGAAGGTGACGGAAATAGGT ACTGGAGAGGAAATGGTTGAGG Xia et al. (2010) 




Table 2. Gene expression for both IL-1ɑ and IL-7 R in liver mice for different treatment. 
 
Gene  Control Yeast Yeast + DMN 35 days Yeast + DMN 60 days DMN 35 days DMN 60 days 
IL-1ɑ 
RQ 1 0.800564 0.87492 2.587842 1.063101 4.653063 
SE 0.04 0.14 0.08 0.09 0.05 0.3 
        
 
IL-7r 
RQ 1 0.540631 0.567112 0.279881 0.751756 1.971113 




Table 3. Fisher's LSD for GOT, GPT and ALP. 
 
Contrast 
GOT GPT ALP 
Significant Difference Significant Difference Significant Difference 
Control-DMN 30 days * -87.6 * -47.4 * -224.8 
Control-DMN 60 days * -110.4 * -57.8 * -259.4 
Control-DMN-Yeast 35 days * -84.8 * -18.4 * -84.4 












DMN 30 days-DMN 60 days * -22.8 * -10.4 
 
-34.6 
DMN 30 days-DMN-Yeast 35 days 
 
2.8 * 29 * 140.4 
DMN 30 days-DMN-Yeast 60 days * 63.6 * 47.8 * 228.6 
DMN 30 days-Yeast * 89.6 * 48.4 * 230.4 
DMN 60 days-DMN-Yeast 35 days * 25.6 * 39.4 * 175 
DMN 60 days-DMN Yeast 60 days * 86.4 * 58.2 * 263.2 
DMN 60 days-Yeast * 112.4 * 58.8 * 265 
DMN-Yeast 35 days-DMN-Yeast 60 days * 60.8 * 18.8 * 88.2 
DMN-Yeast 35 days-Yeast * 86.8 * 19.4 * 90 










slides were prepared to be ready for examination in College of 
Science, Zoology Department, King Saud University, Riyadh, Saudi 
Arabia. For examination in the light microscope, briefly, a field 
containing a portal vein approximately 100 m in diameter in its 
centre was selected at a magnification of 200×. Digitalized images 
of the field and five random fields of the same size were captured 
for computer analysis by a digital camera. The average of the five 




Statistical analysis  
 
The data from each of GOT, GPT and ALP, as well as from RT-
PCR of the gene expression of interleukin 1-alpha (IL-1ɑ) and 
interleukin-7 receptor (IL-7r) was subjected to analysis using 
analysis of variance (ANOVA) test to determine the P-value for the 
different used variables. The Fisher's least significant difference 
(LSD) test was used (within this method, 5.0% risk of calling each 
pair of means significantly different when the actual difference 
equal 0) to find the significant differences between each two 
variables. The results are been summarized in Tables 2, 3 and 4. 
 
 
RESULTS AND DISCUSSION 
 
From Tables 3 and 4 and Figures 1 to 3, it is clear that 
positive and negative controls are nearly same which 
indicate that yeast has no negative effect on the GOT 
liver function and can be used safely. In case of 
treatment with DMN for two weeks, GOT activity 
increased    significantly    after   35   days  and  a  further  








Significant Difference Significant Difference 
Control-DMN 35 days * -1.13812 * -0.36041 
Control-DMN 60 days * -0.31188 * -0.37055 
Control-Yeast * -0.60878 * -0.84901 
Control-Yeast-DMN 35 days * -0.21027 * -0.45532 
Control-Yeast-DMN 60 days * -1.9529 * -0.7347 
DMN 35 days-DMN 60 days * 0.826238 * -0.01014 
DMN 35 days-Yeast * 0.529344 * -0.4886 
DMN 35 days-Yeast-DMN 35 days * 0.927854 * -0.0949 
DMN 35 days-Yeast-DMN 60 days * -0.81478 * -0.37429 
DMN 60 days-Yeast * -0.29689 * -0.47846 
DMN 60-Yeast-DMN 35 days * 0.101615 * -0.08476 
DMN 60 days-Yeast-DMN 60 days  * -1.64102 * -0.36415 
Yeast-Yeast- DMN 35 days * 0.39851 * 0.393694 
Yeast-Yeast-DMN 60 days * -1.34413 * 0.114313 

























increase was shown after 60 days, which prove that the 
liver functions was been impaired by the mutagen DMN. 
This change increased by the time after treatment by 
DMN. This is a clear induction about that liver injury or 
fibrosis has happened. In case of using yeast during the 
treatment with DMN for 35 days, negligible improvement 
in the liver function was shown, and the amount of GOT 
was still high. However, treatments with yeast for 60 days 
showed a significant improvement in the liver function 
and the level of GOT decreased significantly. The same 
results were obtained in case of GPT and ALP.  
Recently Xia et al. (2010)  demonstrated  changes  that  
happened in both of IL-1ɑ as well as IL-7r. This change 
happened during hepatocellular carcinoma, developed 
due to liver injury. These two markers have been used in 
our study to investigate their expression during the 
induction of liver injury. DMN has been used in liver injury 
induction. Interleukin-7 receptor is a protein found in the 
surface of the cell (Huebner et al., 2008). Interleukin-7 
receptor has been reported by different authors to be 
associated with different kind of diseases including liver 
injury, T-cell acute lymphoblastic leukemia and multiple 
sclerosis and rheumatoid arthritis (Nicklin et al., 1994; 
Watson and Miller, 1995;  Al-Rawi et al.,  2003).  IL-1α  is  









































the protein encoded by the IL1a gene (Marchand et al., 
2000). As  a  cytokine,  it  has  many  important  activities 
which have been reported to be influenced when 
physiological changes existed, as well as in the 
hematopoietic and liver injury (Bankers-Fulbright et al., 
1996; Watson and Miller, 1995). Although there are many 
interactions between IL-1α and the other cytokines, the 
most consistent and most clinically relevant is its 
synergism with tumor necrosis factor (TNF) (van Der, 
2005). In this study, as shown in Table 2, it can be 
observed that the normal condition of IL-1ɑ and IL-7r 
expressions in group 1 shows a low level of the 
expressions of both genes. Also, their expressions 
amounts in general, have been increased independently 
from the types of the inducer. Each of yeast and DMN or 
both of them had increased expression of both genes. 
This spots the roles of IL-1ɑ and IL-7r in sensing and 
interacting with any abnormal conditions faced by the 
cells. However, the data tells us that there are two types 
of responses during various treatments; one is positively 
affected and the other is negatively affected. The positive 
affect is mainly due to yeast, where the cells, still normal, 
and the excesses in our genes due to abnormal 
conditions, could be maintained, while  cells  itself  is  still  






    
(a)           (b)  
   
(c)          (d)  
 
Figure 4. (a) Histology of normal control rat liver; (b) pronounced histopathological abnormalities seen in rats 
treated with DMN 35 days; (c) DMN treated (60 days) rat liver showing higher tendency for liver fibrosis 
manifested by the presence of many spots of focal collected cellular granulomatous lesions which showed focal 
collection of inflammatory cells and loss of hepatic tissue structural pattern; (d) treated with only yeast. CV, 
Central vein; BS, blood sinusoids; DHC, degenerated hepatic cord ; PF, periportal fibrosis; RCI, periportal round 




active and viable. This can be concluded from both gene 
expressions by comparing groups 3 and 4 with groups 5 
and 6. Particularly in group 4, both genes showed high 
expressions. However, in case of group 5 and 6, the 
expression in both genes came down. This agrees with 
the data from the histopathology.  
Yeast maintains the cells viability and as a result, 
maintains both gene expressions. From the expression of 
IL-1ɑ in group 2 which shows the highest expression, it is 
clear that yeast is a perfect inducer for that gene and for 
some extent to the IL-7r. The decrease in the expression 
in case of IL-7r, can be explained due to the fact that, the 
cells sensed that the yeast is not that harmful an agent, 
especially if compared with group 5, where DMN existed 
alone. It is clear that yeast, even though it is an inducer, it 
is still a friendly inducer for both genes while cells are still 
viable. DMN is also an inducer but had negative effect on 
the cell viability which can be concluded for the 
expression of both genes in group 6. Time is a critical 
factor. Comparing time can reveal significant conclusions 
about what is going on. IL-1ɑ has been linked to the 
activation of TNFɑ or at least, there is a synergistic 
interaction between both of them, which might reveal that 
IL-1ɑ is a modulator for the endogenous antioxidant 
systems, which is a strong protector against oxidants and 
free-radicals, as well as mutagens (Amro, 2010; 
Dinarello, 2001). 
In case of the data obtained from the histopathology 
examination, they are in agreement with all the above 
results, and yeast shows a significant ability to maintain 
the liver. Light microscopic observation revealed that the 
control, negative control and the groups treated with 
yeast showed normal large polygonal cells with 
prominent round nuclei and eosinophilic cytoplasm, and 
few spaced hepatic sinusoids arranged in between the 
hepatic cords with fine arrangement of Kupffer cells 
(Figures 4a and d). In contrast, groups receiving only 
DMN for 35 days showed massive hepatotoxicity.  
However, DMN alone for 60 days exhibited increased 
hepatotoxicity in comparison to other treatment. The most 




pronounced histopathological abnormalities observed in 
rats treated with DMN are dissolution of hepatic cords, 
which appeared as empty vacuoles aligned by strands of 
necrotic hepatocytes (Figures 4b and c). The hepatic 
tissues showed the presence of dense focal inflammatory 
cells or necrotic tissues. 35 and 60 days treatment of 
DMN alone resulted in common histopathological 
alterations, including perivascular round cell infiltration, 
associated with membrane changes of endothelial lining 
cells manifesting periportal fibrosis, marked degeneration 
of hepatic cords, increased incidence of vacuolar 
degeneration and apoptotic cell death. DMN treatment 
showed higher tendency for liver injury or fibrosis 
manifested by the presence of many spots of focal 
cellular granulomatous lesions. Light microscopic 
observations revealed that DMN at 60 days caused 
massive hepatotoxicity compared to other treatments as 
control, yeast alone and yeast with DMN, including 
dissolution of hepatic cords, focal inflammation and 
necrotic tissues. Interestingly, 35 days of DMN alone also 
exhibited abnormal changes, including periportal fibrosis, 
degeneration of hepatic cords and increased apoptosis. 






DMN is able to induce liver injury in rats. Yeast has no 
side effect on the liver and on GOT, GPT and ALP, but 
induced expression of both IL-1ɑ and IL-7r. The longer 
the yeast feeding time, the better the GOT, GPT and ALP 
activities, and the liver histopathology. IL-1ɑ and 1L-7r 
have different responses for each of DMN and the yeast 
which proves that they are very sensitive for any 
abnormal compounds inside the rats’ bodies. This study 
shows the importance of using yeasts as probiotics in the 





This work was supported by Deanship of Scientific 
Research and Research Centre, College of Pharmacy, 





Al-Rawi MAA, Mansel RE, Jiang WG (2003). Interleukin-7 (IL-7) and IL-
7 receptor (IL-7R) signalling complex in human solid tumours. Histol. 
Histopathol. 18:911-923. 
Amro AA (2010). The philosophy behind exo/endo/existing antioxidants 
and our built-in oxidant and antioxidant system. Pharmazie 
65(10):711-719. 
Bankers-Fulbright JL, Kalli KR, McKean DJ (1996). Interleukin-1 signal 
transduction. Life Sci. 59(2):61-83.  
Brophy S, Burrows CL, Brooks C, Gravenor MB, Siebert S, Allen 
SJ2008). Internet-based randomized controlled trials for the 





    (spondyloarthropathy. BMC Musculoskelet. Disord. 9:4. 
Buts JP (2005). [Lyophilized Saccharomyces boulardii: example of a 
probiotic medicine]. Rev. Gastroenterol. Peru 25:176-188. 
Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, Zhao 
D, Kokkotou EG, Pothoulakis C, Kelly CP (2009). Saccharomyces 
boulardii inhibits EGF receptor signaling and intestinal tumor growth 
in Apc(min) mice. Gastroenterology 137(3):914-923.  
Cohen M (2007). Traveller's 'funny tummy' - reviewing the evidence for 
complementary medicine. Aust. Fam. Phys. 36:335-336. 
Czervoka D, Rampal P (2002). Experimental effects of Saccharomyces 
boulardii on diarrheal pathogens. Microbes Infect. 4:733-739. 
Dinarello CA (2001). IL-1α. In Durum SK, Oppenheim JJ, Feldmann M. 
Cytokine reference: a compendium of cytokines and other mediators 
of host defense. Boston: Academic Press. pp. 307-318. ISBN 0-12-
252673-2. 
Dinarello CA (1997). Induction of interleukin-1 and interleukin-1 receptor 
antagonist. Semin. Oncol. 24(3 Suppl. 9):S9-81-S9-93.  
Gerasimidis K, McGrogan P, Hassan K, Edwards CA (2008). Dietary 
modifications, nutritional supplements and alternative medicine in 
paediatric patients with inflammatory bowel disease. Aliment. 
Pharmacol. Ther. 27:155-165. 
Heilpern D, Szilagyi A (2008). Manipulation of intestinal microbial flora 
for therapeutic benefit in inflammatory bowel diseases: review of 
clinical trials of probiotics, pre-biotics and synbiotics. Rev. Recent 
Clin. Trials 3:167-184. 
Heimbach JT (2008). Health-benefit claims for probiotic products. Clin. 
Infect. Dis. 46 Suppl 2, S122-124; discussion S144-151. 
Huebner J, Franz C, Kopp M (2008). [Probiotics--evidence-based 
medicine or simply hocus-pocus?]. Dtsch. Med. Wochenschr 
133:367-369. 
Kumura H, Tanoue Y, Tsukahara M, Tanaka T, Shimazaki K (2004). 
Screening of dairy yeast strains for probiotic applications. J. Dairy 
Sci. 87:4050-4056. 
Macfarlane GT, Cummings JH (1999a). Probiotics and prebiotics: can 
regulating the activities of intestinal bacteria benefit health? West. J. 
Med. 171:187-191. 
Macfarlane GT, Cummings JH (1999b). Probiotics and prebiotics: can 
regulating the activities of intestinal bacteria benefit health?  Br. Med. 
J. 318:999-1003. 
Marchand J, Vandenplas Y (2000). Micro-organisms administered in the 
benefit of the host: myths and facts. Eur. J. Gastroenterol. Hepatol. 
12:1077-1088. 
Marchand J, Vandenplas Y (2000). Micro-organisms administered in the 
benefit of the host: myths and facts. Eur. J. Gastroenterol. Hepatol. 
12:1077-1088. 
Nicklin MJ, Weith A, Duff GW (1994). A physical map of the region 
encompassing the human interleukin-1 alpha, interleukin-1 beta, and 
interleukin-1 receptor antagonist genes. Genomics 19(2):382-384.  
Rosen LD, Bukutu C, Le C, Shamseer L, Vohra S (2007). 
Complementary, holistic, and integrative medicine: colic. Pediatr. 
Rev. 28:381-385. 
Sullivan A, Nord CE (2003). The place of human probiotics in human 
intestinal infections. Int. J. Antimicrob. Agents 20:313-319. 
van der Aa Kule, Skovgaard K, Jespersen L (2005). In vitro screening of 
probiotic properties of Saccharomyces cerevisae var boulardii and 
foodborne Saccharomyces cerevisiae strains. Int. J. Food Microbiol. 
101:29-40.  
Watson AJ, Hogan A, Hahnel A, Weimer KE, Schultz GA (1992). 
Expression of growth factor ligand and receptor genes in the 
preimplantation bovine embryo. Mol. Reprod. Dev. 31:87-95.    
Watson CJ, Miller WR (1995). Elevated levels of members of the STAT 
family of transcription factors in breast carcinoma nuclear extracts. 
Br. J. Cancer 71:840-844. 
Xia Y, Chen R, Song Z, Ye S, Sun R, Xue Q, Zhang Z (2010). Gene 
expression profiles during activation of cultured rat hepatic stellate 
cells by tumoral hepatocytes and fetal bovine serum. J. Cancer Res. 
Clin. Oncol. 136(2):309-321.  
 
